Current trends in immunosuppressive treatment

Czech version

Authors: Marta Sobotková; Jiřina Bartůňková
Authors‘ workplace: Ústav imunologie 2. LF UK a FN Motol, Praha
Published in: Vnitř Lék 2019; 65(2): 136-142
Category:

Overview

Immunosuppressive agents represent a class of drugs that inhibits activity of the immune system. They are mostly used in autoimmune diseases and other inflammatory conditions treatment and in prevention of recipient´s immune response to donors antigens in transplantations. There is a broad spectrum of different immunosuppressive drugs with various mechanisms of action. This article provides an overview of drugs currently registered as immunosuppressive agents in the Czech Republic and provides some insights what we might expect regarding this group of drugs in the future.

Keywords:

biologic treatment – fusion proteins – Kinase inhibitors – Monoclonal antibodies – tolerance

Sources

Hynie S. Speciální farmakologie. Díl VII/A. Protinádorová chemoterapeutika a imunomodulační látky. 2 vyd. Karolinum: Praha 2003: 104–130. ISBN 80–246–0656–9.
Bartůňková J, Šedivá A, Janda A. Imunodeficience. 2. vyd. Grada: Praha 2007: 192–197.ISBN 978–80–247–1980–1.
Pavelka K, Arenberger P, Lukáš M et al. Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, gastroenterologii a dermatologii. Grada: Praha 2014: 3–7. ISBN 978–80–247–5048–4.
Databáze léků. Státní ústav pro kontrolu léčiv. Dostupné z WWW: <www.sukl.cz>
Lloyd M. Philip Showalter Hench, 1896–1965. Rheumatology (Oxford) 2002; 41(5): 582–584.
Pavelka K, Rovenský J. Klinická revmatologie. Galén: Praha 2003: 773–828. ISBN 80–7262–174–2.
Pavelka K. Nová doporučení pro léčbu revmatoidní artritidy. Postgraduální medicína 2017; 19(1): 6–12.
Murray JE. Nobel Prize Lecture: The first succesful transplant in man. Dostupné z WWW: <https://web.stanford.edu/dept/HPS/transplant/html/murray.html>. [cit. 14. 6. 2018]
Pellegrino B. Immunosuppression. Dostupné z WWW: <https://emedicine.medscape.com/article/432316-overviewServer>.
Matl I. Léčba lupusové nefritidy. Interní Med Praxi 2012; 14(5): 206–208.
Thon V. Teriflunomid v léčbě relabující-remitující formy roztroušené sklerózy – imunomodulační mechanismy. Neurol praxi 2016; 17(1): 52–54.
Thiyagarajan UM, Ponnuswamy A, Bagul A. Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol 2013; 37(6): 586–601. Dostupné z DOI: <http://dx.doi.org/10.1159/000351643>.
Sobotková M, Bartůňková J. Antibiotická imunosupresiva. Remedia 2008; 18(3): 233–241.
Perenyei M, Jayne DR, Floßmann O. Gusperimus: immunological mechanism and clinical applications. Rheumatology (Oxford) 2014; 53(10): 1732–1741. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ket451>.
Imbach P. Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review. Swiss Med Wkly 2012; 142:w13593. Dostupné z DOI: <http://dx.doi.org/10.4414/smw.2012.13593>.
Sobotková M, Bartůňková J. Monoklonální protilátky a další biologická léčiva užívaná v imunosupresivní léčbě. Remedia 2008; 18(5): 356–364.
Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 1996; 6(3): 109–119.
Czajkowsky DM, Hu J, Shao Z et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012; 4(10): 1015–1028. Dostupné z DOI: <http://dx.doi.org/10.1002/emmm.201201379>.
Havrdová E. Fingolimod. Remedia 2011; 21(4): 297–303.
Vašáková M. Pirfenidon v léčbě idiopatické plicní fibrózy. Remedia 2015; 25(1): 61–66.
Šterclová M, Vašáková M. Nintedanib. Remedia 2016; 26(1): 39–42.
Hardinger KL, Brennan DC. Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3(4): 68–77. Dostupné z DOI: <http://dx.doi.org/10.5500/wjt.v3.i4.68>.
White JR, Phillips F, Monaghan T et al. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2018; 47(12): 1610–1622. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.14669>.
Faissner S, Gold R. Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. CNS Drugs 2018; 32(3): 269–287. Dostupné z DOI: <http://dx.doi.org/10.1007/s40263–018–0488–6>.
Paul F, Murphy O, Pardo S et al. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs 2018; 27(3): 265–271. Dostupné z DOI: <http://dx.doi.org/10.1080/13543784.2018.1443077>.
Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007; 7(9): 665–677. Dostupné z DOI: <http://dx.doi.org/10.1038/nri2153>.

Labels

Diabetology Endocrinology Internal medicine

Defensive and damaging inflammation: basic characteristics

IL-1 family cytokines in chronic inflammatory disorders

Heterogeneity of lymphocytes as central operating units of the immune system

Microbiota, immunity and immunologically-mediated diseases

Primary immunodeficiencies in adults

Secondary immunodeficiency as a consequence of chronic diseases

Treatment of antibody immunodeficiency

Adverse effects of immunoglobulin therapy

The role of allergology in internal medicine today and vice versa

Anaphylactic symptoms and anaphylactic shock

Article was published in

Internal Medicine

2019 Issue 2